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Mixed-field agglutination observed in column 
agglutination testing is not always associated 
with the A3 subgroup
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ORiginal RepORt
Mixed-field agglutination (MFA) can be observed in forward 
typing of samples from A3 individuals with serologic ABO typing 
methods. The results of column agglutination testing (CAT) 
and tube agglutination testing using different antibody clones 
can be discordant. In this report, we reveal our experience 
using polymerase chain reaction–sequence-based typing (PCR-
SBT) of ABO exon 7 to clarify serologic method discordance of 
A subgroup blood typing in Northern Thai donors. A total of 21 
group A blood donors with either MFA or weak agglutination on 
routine ABO CAT were recalled. CAT was repeated with human 
and monoclonal anti-A, and tube agglutination testing with 
monoclonal anti-A and PCR-SBT of ABO exon 7 was performed. A 
total of 13 of the 21 donors returned, and ABO CAT with human 
anti-A was repeated. Eleven samples showed MFA suspected to be 
the A3 subgroup, and two samples showed 2+ strength suspected 
to be the Aweak subgroup. When tube agglutination testing using 
monoclonal antibody was performed, MFA was not observed in 
9 of 11 samples with previously observed MFA from routine CAT, 
which were then interpreted as A2. From PCR-SBT performed in 
only exon 7 of the ABO gene, 7 of 13 sample results were consistent 
with ABO*A2 or ABO*AW alleles. Two samples suspected to be 
A2 or A3 had an ABO*AW allele. In two samples suspected to be 
Aweak, no mutation was detected in ABO exon 7, suggesting genetic 
variation elsewhere in the gene. Although other coding exons 
were not examined, in the alleles that could be assigned, ABO*A3 
alleles were found less frequently than would be predicted from 
the serologic findings. These findings suggest that when MFA in 
routine CAT is observed, an A3 subgroup cannot be presumed. 
Caution should be exercised when MFA is noted in routine CAT. 
Immunohematology 2018;34:49–56.
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ABO testing, required in blood donor processing and pre-
transfusion testing, must be accurate to provide compatible 
blood components for transfusion to patients. If ABO 
discrepancy—when the red blood cell (RBC) testing result 
using commercial antisera (forward type) does not agree with 
the serum/plasma testing result using reagent RBCs (reverse 
type)—occurs either in donors or recipients, additional testing 
is needed to resolve the typing.1,2 ABO discrepancies can be 
caused by technical errors or sample-specific characteristics, 
including weak or variant antigen expression. Technical errors 
should be ruled out initially. If no problems with technique 
(including reagents and equipment) are identified, the samples 
should be examined. Weak or missing reactivity, extra 
reactivity, and mixed-field agglutination (MFA)—characterized 
by distinct agglutinated cells mixed with many unagglutinated 
cells—can occur in both RBC and serum/plasma testing and 
can result in an ABO typing discrepancy. This report focuses 
on weak reactivity and MFA in blood group A individuals.
Possible causes of ABO discrepancies associated with 
weakly expressed antigens observed when the RBCs were 
typed with anti-A include a subgroup of A, recent transfusion, 
stem cell transplantation, or malignancy.2 We investigated 
the expression of subgroups of A because our healthy donors 
had no history of transfusion, transplantation, or serious 
medical condition. Within the A group, A1 and A2 subgroups 
are the most common. A1 represents about 80 percent and A2 
represents about 20 percent of group A donors.1,2 Subgroups 
such as A3, Am, Ax, and Ael are found infrequently. These 
subgroups show weaker reactivity with anti-A reagents, mostly 
with human polyclonal antibody but also with monoclonal 
antibody, and can cause ABO discrepancies.1 These variants 
result from genetic variation within the ABO gene producing 
amino acid substitutions in the glycosyltransferases.1,3–5
In Thailand, most blood bank laboratories perform 
routine ABO serologic testing using either tube agglutination 
testing or automated column agglutination testing (CAT). 
Although CAT is widely used in heavy workload laboratories 
such as the Thai Red Cross Society, in tertiary hospitals and 
university hospitals, tube agglutination testing is still the gold 
standard of serologic testing. Because there is no regulatory 
requirement regarding ABO discrepancy resolution in 
Thailand, the Thai Red Cross Society suggests that hospital-
based transfusion service laboratories follow AABB guidelines 
in the interpretation of serologic reactivity and the initial 
investigation of the discrepancy.1 When the discrepancy is 
resolved, the final ABO group, the reasons for the discrepancy, 
and the methods of resolution are recorded in the blood bank 
section of the donor record, and the donor is informed. If the 
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donor is determined to be a subgroup of A without any clinically 
significant antibodies, the blood units would be labeled with 
the name of the subgroup and could be transfused to patients 
of group A or AB or the identical subgroup. If, however, the 
discrepancy cannot be resolved by the hospital’s blood bank by 
any method, then a blood sample can be sent to the Thai Red 
Cross Society for confirmation. Testing at the Thai Red Cross 
Society includes conventional tube testing for cell and serum 
grouping; RBC testing with anti-A,B, anti-A1, and anti-H; 
testing with lectins; adsorption-elution testing; and saliva 
testing. In some cases, samples for molecular testing might 
be sent out (personal communication from Department of 
Histocompatibility and Immunogenetics Laboratory, National 
Blood Center, Thai Red Cross Society). This additional testing 
often will delay the interpretation of the ABO group such that 
the blood unit will not be released for transfusion.
Serologic-based reagents should be expected to 
differentiate between A subgroups because weak or no 
agglutination can lead to wrong ABO group interpretation 
and the possible transfusion of a weak A subgroup to a group 
O recipient. This ABO-incompatible transfusion may lead to 
shortened survival of transfused RBCs in these recipients.6 
Correct differentiation is important for selection of blood 
products for routine transfusion; thus, accurate ABO typing 
provides transfusion safety. Moreover, differentiation of 
A subgroup donors is beneficial in solid organ transplant 
candidates. Placing a kidney from group A2 living donors into 
group O or B recipients provides an excellent outcome with 
immediate function of the allograft and less graft rejection 
because of the small amount of A antigens in the donor graft. 
The use of A2 donors can also expand the donor pool.7 It has 
been suggested that the use of molecular testing for A1 and A2 
subgroups be performed before elective transplantation.7
In our university teaching hospital, ABO typing is 
routinely performed by CAT and follows AABB guidelines 
for ABO discrepancy resolution.1 When weak agglutination 
or MFA is observed, the donor’s medical history is reviewed, 
and the sample is retested by the same CAT card type to rule 
out technical error. Because the degree of reactivity with 
monoclonal reagents can vary,1 retesting with anti-A from a 
different monoclonal clone, namely one from Thai Red Cross 
Society with anti-A1 specificity, and with anti-H lectin is 
performed by tube agglutination testing. If the RBCs do not 
agglutinate with this monoclonal anti-A1, the A2 subgroup 
might be suspected.8 If MFA is again seen and this anti-A1 
result is positive, then we presume this sample is of the A3 
subgroup.8 When discordancy between CAT and the tube 
agglutination method is observed, however, the result is 
inconclusive. In the present study, polymerase chain reaction–
sequence-based typing (PCR-SBT) of ABO exon 7 was used 
to help clarify the serologic discrepancies in those samples. 
Because molecular testing is not implemented in either our 
facility or the Thai Red Cross Society’s protocol, this testing 




From 1 January through 31 December 2015, we identified 
21 donors with either the rare MFA pattern or only a 2+ or 
less reaction on ABO CAT with human antisera among all 
23,918 donor blood units routinely tested at the blood bank of 
the Maharaj Nakorn Chiang Mai Hospital (study approval by 
the ethics committee at the Faculty of Medicine, Chiang Mai 
University; study code NONE-2558-02885). This 1400-bed, 
Table 1. Primer sequences for PCR and DNA sequencing
Primer name Sequences (5´  3´) Types Product size (bp)




For exon 7 sequencing





ABO-3´UTR See sequence above Reverse
PCR = polymerase chain reaction; bp = base pair.
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medical-teaching, tertiary-care hospital serves the northern 
region of Thailand. These 21 donors were contacted and 
requested to return to provide an additional 20-mL sample of 
blood collected in EDTA tubes to repeat the CAT and perform 
additional ABO tests including tube agglutination testing and 
PCR-SBT.
ABO Phenotyping by CAT
Forward typing and reverse typing were performed using 
two types of gel cards: the ABO/D + Reverse Grouping card 
and the DiaClon ABO/D + Reverse Grouping card (Bio-Rad 
Laboratories, Cressier, Switzerland). The ABO/D + Reverse 
Grouping card contains a mixture of human polyclonal and 
monoclonal anti-A (cell line: A5) (referred to as “CAT with 
human antisera” in this report), and the DiaClon ABO/D+ 
Reverse Grouping card contains monoclonal anti-A (cell 
line: A5) (referred to as “CAT with monoclonal antisera” in 
this report). Testing procedures were performed following 
manufacturer instructions.
ABO Phenotyping by Tube Agglutination Test
Forward typing was performed by testing 5 percent RBC 
suspensions from each donor with monoclonal anti-A (cell 
line: combination of 3C4, 6G4, 16G4, and LM103), anti-B, 
anti-A,B, anti-A1 (cell line: 6C10), and anti-H lectin (extract 
of Ulex europaeus) (Thai Red Cross Society). RBCs were 
washed three times with normal saline to avoid spontaneous 
agglutination and nonspecific aggregation.1 Reverse typing 
was also performed by testing two drops of plasma with 
5 percent group A1, B, and O cells (prepared in-house). 
After centrifugation, the agglutination reaction was graded, 
interpreted, and classified for the resulting ABO subgroups 
according to the AABB Technical Manual.1
ABO Gene Sequencing by PCR-SBT
Genomic DNA samples were prepared from EDTA-
anticoagulated blood using the Purelink Genomic DNA Mini 
Kit (Invitrogen, Thermo Fisher Scientific, Waltham, MA). PCR 
was performed using primers specific for exon 7 of the ABO 
gene: forward primer ABO-Ex7 and reverse primer ABO-
3´UTR, both providing 725 bp PCR product (Table 1). The 
PCR mixture included 150 ng genomic DNA, 0.3 µmol/L gene-
specific primers, 1× buffer for KOD-Plus-Neo, 0.2 mmol/L 
dNTP each, 1.5 mmol/L MgSO4, and 1 U KOD-Plus-Neo 
(Toyobo, Osaka, Japan) in 50 μL reaction volume. The cycling 
condition was the step-down cycle according to the KOD-Plus-
Neo kit’s instructions: 2 minutes at 94°C for 1 cycle, 10 seconds 
at 98°C and 30 seconds at 74°C for 5 cycles, 10 seconds at 
98°C and 30 seconds at 72°C for 5 cycles, 10 seconds at 98°C 
and 30 seconds at 70°C for 5 cycles, 10 seconds at 98°C and 
30 seconds at 68°C for 30 cycles, and 7 minutes at 68°C for 
the final extension. The PCR products were fractioned on a 1 
percent agarose gel containing 0.4 μg/mL ethidium bromide 
and then purified using the Purelink Quick Gel Extraction Kit 
(Invitrogen). Nucleotide sequencing was carried out via Sanger 
sequencing on ABI3730XL (Bio Basic Canada, Markham, 
Canada) using six primers (Table 1). The Sanger contig 
overlapping nucleotide segments representing consensus 
sequences were analyzed based on information from the Blood 
Group Antigen Gene Mutation Database9 and the alleles table 
constructed by the International Society of Blood Transfusion 
Red Cell Immunogenetics and Blood Group Terminology.10
Family Studies
Returning donors were interviewed for medical and family 
history. The donation history of all donors in our laboratory’s 
records were reviewed. Their family members were encouraged 
to also participate in this study. After signing the consent form, 
a 20-mL blood sample was collected in EDTA tubes to perform 
ABO testing by CAT, tube agglutination testing, and PCR-SBT.
Results
Subjects Studied
During the 2015 study year, among the 23,918 routine 
CATs performed in blood donors at our hospital, group A 
donors constituted 4847 (20.3%) and group AB donors 1459 
(6.1%), group B donors numbered 7343 (30.7%), and group 
O 10,269 (42.9%). Among the 6306 group A and AB donors, 
we identified 19 (0.30%) with MFA patterns, and 2 (0.03%) 
donors demonstrated weak (2+) expression by routine CAT 
with human antisera. The prevalence of ABO phenotypes 
in our study of Thai donors was similar to that reported in 
previous studies in which blood group O was approximately 
40 percent, group B was 30 percent, group A was 20 percent, 
and group AB was 10 percent.11–13 Among group A, the Thai 
Red Cross reported in 2017 that the frequency of A3 and A3B 
classified by MFA detection from tube agglutination testing 
was 0.04 percent and 0.46 percent, respectively.14
Of 21 donors who were contacted, a total of 13 (62%) 
returned, consented to participate in this study, and provided 
additional blood samples (11 with MFA patterns and 2 with 
2+ agglutination). From the review of medical and donation 
histories, none of the donors had previous non-ABO group-
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specific RBC component transfusion, ABO-mismatched stem 
cells or bone marrow transplants, or history of malignancy. 
Therefore, weak antigen expression or MFA is likely due to a 
genetic factor. Five of the 13 donors (donors 3, 9, and 11–13) 
had previously donated more than three times and had the 
alert message in the hospital’s donation record as “suspected 
subgroup.” The other eight donors were first-time blood donors 
to the center.
Discordant Results of Blood Group Serologic Tests
Table 2 shows the agglutination reaction strength of the 
returning 13 donors from CAT and tube agglutination testing. 
From routine CAT with human antisera, the 11 donors with 
MFA in forward typing were interpreted to be in the A3 
subgroup (donors 1–11). The two donors with 2+ agglutination 
strength were suspected to be of the Aweak subgroup (donors 12 
and 13). Reverse typing of all 13 studied donors showed the 
typical agglutination pattern of blood group A.
The results of CAT revealed differences in the reaction 
patterns of forward typing between CAT with human antisera 
N. Anukul et al.
Table 2. Serologic results of samples from 21 donors
Forward typing Reverse typing
Donor ID Test method* anti-A anti-B anti-A,B anti-A1 anti-H lectin A1 cell B cell O cell
1 CAT human antisera mf neg ND ND ND neg 4+ ND
CAT monoclonal antisera mf neg ND ND ND neg 4+ ND
Tube 2+mf neg 2+mf wk 4+ neg 4+ neg
2 CAT human antisera mf neg ND ND ND neg 4+ ND
CAT monoclonal antisera mf neg ND ND ND neg 4+ ND
Tube 2+mf neg 2+mf 1+ 4+ neg 4+ neg
3–8 CAT human antisera mf neg ND ND ND neg 4+ ND
CAT monoclonal antisera mf neg ND ND ND neg 4+ ND
Tube 4+ neg 4+ neg 4+ neg 4+ neg
9 CAT human antisera mf 4+ ND ND ND neg neg ND
CAT monoclonal antisera mf 4+ ND ND ND neg neg ND
Tube 4+ 4+ 4+ neg 2+ neg neg neg
10, 11 CAT human antisera mf 4+ ND ND ND neg neg ND
CAT monoclonal antisera 4+ 4+ ND ND ND neg neg ND
Tube 4+ 4+ 4+ neg 2+ neg neg neg
12 CAT human antisera 2+ 4+ ND ND ND neg neg ND
CAT monoclonal antisera mf 4+ ND ND ND neg neg ND
Tube 4+ 4+ 4+ neg 2+ neg neg neg
13 CAT human antisera 2+ 4+ ND ND ND neg neg ND
CAT monoclonal antisera mf 4+ ND ND ND neg neg ND
Tube 2+ 4+ 4+ neg 2+ neg neg neg
14 CAT human antisera† mf neg ND ND ND neg 4+ ND
15 CAT human antisera† mf neg ND ND ND neg 4+ ND
16 CAT human antisera† mf neg ND ND ND neg 4+ ND
17 CAT human antisera† mf neg ND ND ND neg 4+ ND
18 CAT human antisera† mf 4+ ND ND ND neg neg ND
19 CAT human antisera† mf neg ND ND ND neg 4+ ND
20 CAT human antisera† mf 4+ ND ND ND neg neg ND
21 CAT human antisera† mf 4+ ND ND ND neg neg ND
* Mixed-field agglutination in the tube agglutination test is distinct agglutinated cells with 2+ reaction strength mixed with many unagglutinated cells that can be 
confirmed under light microscope. Mixed-field agglutination in CAT is agglutinated RBCs in the upper half of the gel column with no agglutinated cells at the 
bottom.
†Samples from donors 14–21 were tested with only routine CAT human antisera, since they did not return to our laboratory for additional testing.
ID = identification; CAT = column agglutination testing; mf = mixed-field agglutination; neg = negative; ND = not done; wk = weak agglutination.
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and CAT with monoclonal antisera. When using CAT with 
monoclonal antisera, only 9 of the 11 donors showed MFA 
(donors 1–9) and the other two showed 4+ strength (donors 
10 and 11). For donors 12 and 13, weak A expression without 
MFA was observed by using CAT with human antisera, 
and MFA could be observed by using CAT with monoclonal 
antisera.
The tube agglutination test found MFA only in donors 1 
and 2 and weak A expression only in donor 13. The other donor 
samples showed the expected results of the typical A blood 
group with strong reaction strength (Table 2). When testing 
RBCs with anti-A1, however, the RBCs of 11 of the 13 donors 
were not agglutinated by the anti-A1 and thus were re-typed 
by our study as the A2 subgroup. Also, the RBCs of donors 1 
and 2 were agglutinated by anti-A1 and thus re-typed as the 
A3 subgroup8 (Table 3).
Because the agglutination patterns between CAT and tube 
agglutination testing were significantly different, the ABO 
phenotypes of these 13 donors could not be concluded. We 
thus performed ABO exon 7 sequencing to aid in the prediction 
of the subgroup.
A Allele Sequencing Results
The ABO exon 7 sequencing results of each donor were 
compared with the Blood Group Antigen Gene Mutation 
Database, and nucleotide variants were identified by 
comparing the observed sequence in the coding sequence of 
A allele located at nucleotide 375-1065 (Table 3). Probable 
alleles were assigned based on the nomenclature of ABO alleles 
(Table 3). The variant sequences of all samples were found in 
heterozygosity. Seven samples (3–9) contained two variants, 
c.467C>T and c.1061delC, known to be found in multiple 
alleles of ABO*A2 and ABO*AW. These findings rule out the A3 
subgroup. Three samples (1, 2, and 10) carry ABO*AW31.01 or 
ABO*AW31.02-05 alleles, which would be the Aweak subgroup. 
The remaining samples (11–13) had no changes in exon 7, 
which suggests that changes are present in other regions of the 
gene. Additional sequence-based typing would be necessary to 
assign alleles in these cases.
Discussion
In this study, we report our experience with A subgroup 
typing of Northern Thai blood donors in an attempt to clarify 
the discordant results between routine CAT and tube 
agglutination testing by PCR-SBT of ABO exon 7. Interestingly, 
the results from tube agglutination tests were found to 
correlate more with PCR-SBT. Only two samples (of 13) 
showed correlation between tube agglutination testing and 
CAT in MFA detection, whereas the remainder (11 of 13) were 
discordant. These 11 samples were initially identified as the 
A3 subgroup from CAT with human antisera, but later were 
identified as the A2 subgroup from tube agglutination testing 
with monoclonal antibody. Using different sources and types 
of antisera may have led to these discordant results. Langston 
et al.15 showed that when weak A and weak B are tested by 
Group A serologic method typing discordancy
Table 3. ABO interpretation for 13 donors by CAT, tube agglutination testing, and PCR-SBT









anti-A1 Nucleotides in exon 7 that differ from consensus
Probable allele  
(name based on ISBT allele terminology)†
1, 2 A3 A3 A3 A3 c.646T/A; c.681G/A; c.771C/T; c.829G/A ABO*AW.31.01, ABO*AW31.02-05
3–8 A3 A3 A A2 c.467C/T; c.1061delC/C ABO*A2.01, ABO*A2.14, ABO*A2.15,
9 A3B A3B AB A2B c.467C/T; c.1061delC/C ABO*A2.16, ABO*AW.02, ABO*AW.03, 
ABO*AW.09, ABO*AW.16, ABO*AW.17, 
ABO*AW.18, ABO*AW.45
10 A3B AB AB A2B c.646T/A; c.681G/A; c.771C/T Suspected novel allele‡
11, 12 AweakB A3B AB A2B c.467C/T ABO*A1.05, ABO*A1.06, ABO*A1.07
ABO*A2.10, ABO*A2.11, A215, Aw43, A312, 
Ax26
13 AweakB A3B AweakB A2B None ABO*IVS2+3G (A3), ABO*248G (Aweak), 
ABO*IVS1+5859C (Am), ABO*52T (Ael), 
ABO*119A (Ax), and ABO*188A,189T (Aint)
†Because other exons of the ABO gene were not analyzed, the variant sequences found in all donors may be consistent with more than one allele.
‡Full-gene sequencing is further required to confirm the actual allele.
CAT = column agglutination testing; PCR-SBT = polymerase chain reaction–sequence-based typing; ID = identification; ISBT = International Society of Blood 
Transfusion.
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CAT with both monoclonal and polyclonal antisera, mistyping 
can occur. Even when the same type of antisera (monoclonal) 
were used, the results were discordant between methods. This 
finding was most likely because the monoclonal antibodies 
produced by different cell lines recognize different epitopes of 
the A or B antigen.16 Such discordance has not been observed 
in typical ABO testing, however, and several previous studies 
have reported the correlation between the tube agglutination 
tests and CAT in ABO typing.15,17–19 From our results, CAT 
seems to be more sensitive than the tube agglutination method 
in terms of detecting MFA and weak agglutination correlated 
to the previous reports from other CAT systems such as 
AutoVue Innova and WaDiana Compact. Through the use of 
these systems, two-cell populations were easily observed.20 
From this point of view, there should be awareness when 
selecting the ABO typing method and the source of commercial 
antibodies to be used in a routine laboratory. Some antibody 
clones may not detect weak antigen expression, resulting in a 
different interpretation.
The importance of subgroup identification in donors is 
distinct from that in patients. Although the blood units from 
the subgroup of A blood donors without clinically significant 
anti-A1 or other antibodies can be transfused to typical blood 
group A or AB individuals, once ABO discrepancy occurs, 
resolution is required to identify the true blood group of such 
blood units before they are released for transfusion to avoid 
adverse reaction. Moreover, all the donor’s data will then be 
recorded in the laboratory information system, and the true 
blood group will be recorded in the hospital information 
system. Such data will be useful for transfusion purposes if 
this donor returns to the hospital as a patient in the future. 
Note, however, that sequencing of ABO is not a licensed 
method and should be interpreted with caution, especially 
when incomplete, as in our cases.
ABO genotyping has not been implemented for routine 
use in donor centers or hospital laboratories. SBT may be 
useful for predicting ABO variants but is not ideal for routine 
ABO typing, since it is more time-consuming and expensive 
than serologic testing, which is simpler and more rapid.21,22 
Moreover, SBT, when it does not cover the entire coding or 
gene region, can result in an inability to assign alleles or an 
inaccurate interpretation of alleles. Additionally, predictions 
may be inaccurate because of alterations of gene expression 
unrelated to the gene regions interrogated.21,22 In our study, 
we used SBT of ABO exon 7 as an additional test, along with 
additional serologic testing, to explore the genetic cause of 
subgroup variation and resolve ABO discrepancy.1
Because the majority of single nucleotide polymorphisms 
in the ABO coding region are located in exon 7 of the ABO 
gene and because of limited resources, we selected to examine 
exon 7 to identify the types of A allele. The cost of ABO exon 
7 genotyping by PCR-SBT is approximately $150 per sample. 
In our study, PCR-SBT was performed only on samples 
with inconclusive results from the two accepted methods of 
serologic testing. Among our A subgroup donors, mutations 
at c.467C>T and c.1061delC of the ABO*A2.01 allele were 
common, as reported in other populations.23–25 Two group 
AB donors with the Aweak subgroup exhibited the ABO*A1.02 
allele with c.467C>T, which is common in individuals of Asian 
descent,26 and one group AB donor exhibited no changes in 
exon 7 of the A allele. This finding suggests that other variants 
may be present in the other exons and/or introns of the ABO 
gene.
Because this study sequenced only ABO exon 7, we 
recognize that there is a limitation that genetic variation may 
be missed and allele assignments may be incorrect. Table 3 lists 
the probable allele assignment as well as other possible alleles 
for each sample. In samples 3–9, c.467C>T and c.1061delC 
were also consistent with alleles ABO*A2.14 and ABO*A2.15, 
which share coding sequence with ABO*A2.01, and with 
alleles ABO*A2.16, ABO*AW.02, ABO*AW.03, ABO*AW.09, 
ABO*AW.16, ABO*AW.17, ABO*AW.18, and ABO*AW.45, which 
do not share coding or splice site sequence with ABO*A2.01. 
In donors 1 and 2, ABO*AW31.02-05 allele was detected, and 
if exon 6 had been analyzed and c.297A>G had been found, 
ABO*AW31.01 allele would be concluded. In donor 10, a 
novel allele was identified that is similar to ABO*AW31.01 but 
without c.829G>A. No genetic variants were found in ABO 
exon 7 in donor 13. Based on the serology, it is possible that 
this donor carries one or more variants in ABO gene regions 
not interrogated by this study. Therefore, extending the 
sequencing to the other exons would be useful to identify the 
specific allele.
In conclusion, although CAT can perform blood grouping 
of typical ABO samples with accuracy that is comparable to 
tube agglutination testing, for A subgroups, CAT is more 
sensitive in MFA detection, but interpretation may differ from 
tube agglutination testing and PCR-SBT. From this study 
with only ABO exon 7 sequencing, ABO*A3 alleles were less 
frequent than expected. Hence, observing MFA from routine 
CAT does not imply an A3 subgroup and requires additional 
testing. We explored the use of ABO exon 7 sequencing to 
help clarify inconclusive results from the serologic methods; 
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this molecular testing can be an option in these inconclusive 
cases.21,22
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